Evogene Ltd. (NASDAQ:EVGN) has amended its corn disease resistance research collaboration with Bayer’s (OTCPK:BAYRY) Crop Science Division to focus on identifying genome editing targets that may have potential against a broad range of corn diseases.
The Israeli biotech, through its Ag-Seeds unit, will leverage its Computational Predictive Biology (CPB) platform to identify genetic edits that could improve disease resistance in corn.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.